Estimating survival in patients with lung cancer and brain metastases an update of the graded prognostic assessment for lung cancer using molecular markers (Lung-molGPA)

JAMA Oncology

Volumn 3, Issue 6, 2017, Pages 827-831

  Sperduto, Paul W ^a   Yang, T Jonathan ^b   Beal, Kathryn ^b   Pan, Hubert ^c   Brown, Paul D ^c   Bangdiwala, Ananta ^d   Shanley, Ryan ^d   Yeh, Norman ^e   Gaspar, Laurie E ^e   Braunstein, Steve ^f   Sneed, Penny ^f   Boyle, John ^g   Kirkpatrick, John P ^g   Mak, Kimberley S ^h   Shih, Helen A ^h   Engelman, Alex ⁱ   Roberge, David ^j   Arvold, Nils D ^k   Alexander, Brian ^k   Awad, Mark M ^l   Contessa, Joseph ^l   Chiang, Veronica ^l   Hardie, John ^m   Ma, Daniel ^m   Lou, Emil ^a   Sperduto, William ^a,g   Mehta, Minesh P ⁱ   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF DENVER   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DUKE UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ UNIVERSITY OF MARYLAND   (United States)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k DANA FARBER CANCER INSTITUTE   (United States)

^l YALE UNIVERSITY   (United States)

^m MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; TUMOR MARKER;

ADENOCARCINOMA; AGED; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; EPIDEMIOLOGY; FEMALE; HUMAN; LUNG NEOPLASMS; MALE; METABOLISM; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; RETROSPECTIVE STUDY; SECONDARY;

ADENOCARCINOMA; AGED; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES;

EID: 85016614145     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3834     Document Type: Article

References (15)

1. Torre LA, Bray F, Siegel R.L., Ferlay J., Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66(1):7-30.
3. Gavrilovic IT, Posner JB Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005; 75(1):5-14.
4. Park DM, Posner JB Management of intracranial metastases: history. In: Sawaya R, ed. Intracranial Metastases: Current Management Strategies. Oxford, England: Blackwell Publishing Ltd; 2004:3-19.
5. Rosell R, Carcereny E, Gervais R., et al; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-246.
6. Shaw AT, Kim DW, Nakagawa K, et al Crizotinib versus chemotherapy inadvanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25):2385-2394.
7. Borghaei H, Paz-Ares L, Horn L., et al. Nivolumab vs docetaxel inadvanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373 (17):1627-1639.
8. Garon EB, Rizvi NA, Hui R, et al; KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372 (21):2018-2028.
9. Gaspar L, Scott C, Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37(4):745-751.
10. Sperduto PW, Kased N, Roberge D., et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012; 30(4):419-425.
11. Sperduto PW, Yang TJ, Beal K, et al The effect of gene alterations and tyrosine kinase inhibition on survival and cause of death in patients with adenocarcinoma of the lung and brain metastases. Int J Radiat Oncol Biol Phys. 2016; 96(2):406-413.
12. Sperduto PW, Shanley R, Luo X., et al. Secondary analysis of RTOG 9508, aphase3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). Int J Radiat Oncol Biol Phys. 2014; 90(3):526-531.
13. Aoyama H, Tago M, Shirato H; Japanese Radiation Oncology Study Group 99-1 (JROSG 99-1) Investigators. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: secondary analysis of the JROSG 99-1 randomized clinical trial. JAMA Oncol. 2015; 1(4): 457-464.
14. Johung KL, Yeh N, Desai N.B., et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small cell lung cancer and brain metastasis. J Clin Oncol. 2015; 2016; 34(2): 123-129.
15. Yamamoto M, Serizawa T, Shuto T., et al. Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. Lancet Oncol. 2014; 15(4):387-395.